RNAV8 Bio Joins Team Selected for ARPA-H Funding to Develop Programmable RNA Medicines

PartnershipPROPEL programPositive

AI Analysis

Summary

RNAV8 Bio received a pilot award of up to $4.4 million from ARPA-H to develop the PROPEL program, which aims to create logic-gated RNA therapies that control gene expression through RNA structure without altering the genome.

Outcome Details

Selected for ARPA-H pilot award of up to $4.4 million over one year to develop logic-gated RNA therapies

Importance:5/10

Sentiment:

0.70

RNA therapeuticsARPA-H fundinggene expressionlogic-gated RNAprogrammable medicines

Related Companies

$STTK

Read the original article

Published by PR Newswire Clinical Trials on September 1, 2026 1:00 PM

Read Original